Hookipa Pharma Logo Square.png
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
January 04, 2023 07:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
December 15, 2022 07:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Hookipa Pharma Logo Square.png
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
November 30, 2022 07:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update
November 14, 2022 07:00 ET | HOOKIPA Pharma Inc.
Major oncology collaboration and license agreement secured with Roche to develop HB-700 for KRAS-mutated cancers and an additional undisclosed oncology candidateInvestigational New Drug Application...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022
November 07, 2022 07:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
Hookipa Pharma Logo Square.png
HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
November 02, 2022 07:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Hookipa Pharma Logo Square.png
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
October 20, 2022 07:00 ET | HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
September 07, 2022 07:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
August 11, 2022 07:00 ET | HOOKIPA Pharma Inc.
HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underwayUS Food and Drug Administration accepted HOOKIPA’s Investigational...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
August 04, 2022 07:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...